Search bioRxiv⌕ Search

Biology subjects

Hu, z.

Publications and source records attributed to Hu, z..

1 recordsLinked to original sources

Midkine and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma: evidence from Mendelian randomization, multi-omics factor analysis, and single-cell transcriptomics

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, in part because its tumor microenvironment actively suppresses antitumor immunity. Midkine (MDK) is a secreted heparin-binding growth factor that is overexpressed in a majority of PDAC tumors, but whether it contributes causally to disease risk and through which cell types it acts have not been firmly established. We combined cis-eQTL Mendelian randomization (GTEx pancreas, n = 328 donors; FinnGen PDAC, 1,252 cases) with multi-omics factor analysis (MOFA) of TCGA-PAAD tumors (n = 149), single-sample gene set enrichment analysis (ssGSEA), cross-species single-cell RNA sequencing, and DepMap CRISPR dependency screening. Mendelian randomization identified MDK as the only gene passing false discovery rate correction for PDAC risk (inverse-variance-weighted odds ratio 1.51, 95% CI 1.19-1.91, p = 6.7 x 10??; FDR = 0.008), with concordant direction across five methods and five independent GWAS. MDK was overexpressed in tumors relative to adjacent normal tissue in an independent cohort (GSE62452, n = 130, p = 5 x 10??), and high expression was associated with shorter overall survival (10.2 versus 21.1 months, p = 0.023). In the MOFA decomposition, MDK localized to a factor characterized by tertiary lymphoid structure gene expression but negative correlation with dendritic cells and macrophages, a pattern consistent with immune exclusion. Single-cell analysis and published functional studies indicated that MDK is produced by cancer-associated fibroblasts and endothelial cells rather than by tumor epithelium, and DepMap data confirmed that MDK is not a cell-autonomous fitness gene. Collectively, these results support a model in which MDK acts through the stromal-immune compartment rather than through tumor cell-intrinsic mechanisms, and raise the possibility that MDK blockade could restore antitumor immunity in PDAC.

genomics↗